Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.4%

3 terminated/withdrawn out of 68 trials

Success Rate

93.8%

+7.2% vs industry average

Late-Stage Pipeline

12%

8 trials in Phase 3/4

Results Transparency

0 of 45 completed trials have results

Key Signals

14 recruiting

Enrollment Performance

Analytics

Phase 2

5(29.4%)

Phase 3

4(23.5%)

Phase 4

4(23.5%)

N/A

3(17.6%)

Phase 1

1(5.9%)

17Total

Phase 2(5)

Phase 3(4)

Phase 4(4)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (68)

Showing 20 of 68 trials

NCT07563595Not Yet Recruiting

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT05517265Completed

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)

Role: lead

NCT07559799Not Yet Recruiting

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)

Role: lead

NCT06976918Recruiting

Registry Platform Myelofibrosis and Anemia

Role: lead

NCT06181734Completed

Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC

Role: lead

NCT04290806Recruiting

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Role: lead

NCT05129969Recruiting

Registry Platform Ovarian and Endometrial Cancer

Role: lead

NCT06043011Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Role: lead

NCT03308474Recruiting

Myeloma Registry Platform (MYRIAM)

Role: lead

NCT05954780Active Not Recruiting

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT07240662Recruiting

Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma

Role: lead

NCT06743035Recruiting

Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

Role: lead

NCT06619275Completed

Ripretinib (QINLOCK®) According to Current SmPC

Role: lead

NCT05253911Completed

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

Role: lead

NCT06607302Recruiting

Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study

Role: lead

NCT02970747Completed

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Role: lead

NCT05326308Recruiting

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Role: lead

NCT03374267Recruiting

Registry Platform Urologic Cancer

Role: lead

NCT00910819Completed

Tumour Registry Colorectal Cancer

Role: lead

NCT03417115Active Not Recruiting

Breast Cancer Registry Platform

Role: lead